Technical Analysis for RZLT - Rezolute, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical RZLT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 3.88% | |
| 180 Bearish Setup | Bearish Swing Setup | 3.88% | |
| Expansion Breakdown | Bearish Swing Setup | 3.88% | |
| Reversal New Lows Setup | Bearish Swing Setup | 3.88% | |
| Stochastic Reached Oversold | Weakness | 3.88% | |
| Outside Day | Range Expansion | 3.88% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 21 hours ago |
| 3x Volume Pace | about 23 hours ago |
| 2x Volume Pace | about 23 hours ago |
| 1.5x Volume Pace | about 23 hours ago |
| Down 5% | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Clinical Medicine Diabetes Monoclonal Antibody Cancer Treatments Insulin Specialty Drugs Metabolic Disease Diabetes Mellitus Diabetic Retinopathy Macular Edema Metabolic Diseases Diabetic Macular Edema Kallikrein Plasma Kallikrein
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Clinical Medicine Diabetes Monoclonal Antibody Cancer Treatments Insulin Specialty Drugs Metabolic Disease Diabetes Mellitus Diabetic Retinopathy Macular Edema Metabolic Diseases Diabetic Macular Edema Kallikrein Plasma Kallikrein
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.5 |
| 52 Week Low | 3.1 |
| Average Volume | 9,808 |
| 200-Day Moving Average | 15.73 |
| 50-Day Moving Average | 10.19 |
| 20-Day Moving Average | 7.37 |
| 10-Day Moving Average | 7.07 |
| Average True Range | 0.91 |
| ADX | 21.13 |
| +DI | 15.27 |
| -DI | 20.61 |
| Chandelier Exit (Long, 3 ATRs ) | 7.25 |
| Chandelier Exit (Short, 3 ATRs ) | 8.82 |
| Upper Bollinger Band | 8.38 |
| Lower Bollinger Band | 6.35 |
| Percent B (%b) | 0.17 |
| BandWidth | 27.57 |
| MACD Line | -0.93 |
| MACD Signal Line | -1.05 |
| MACD Histogram | 0.1226 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.10 | ||||
| Resistance 3 (R3) | 8.05 | 7.54 | 7.86 | ||
| Resistance 2 (R2) | 7.54 | 7.18 | 7.56 | 7.78 | |
| Resistance 1 (R1) | 7.12 | 6.97 | 7.33 | 7.17 | 7.71 |
| Pivot Point | 6.61 | 6.61 | 6.72 | 6.63 | 6.61 |
| Support 1 (S1) | 6.19 | 6.25 | 6.40 | 6.24 | 5.69 |
| Support 2 (S2) | 5.68 | 6.04 | 5.70 | 5.62 | |
| Support 3 (S3) | 5.26 | 5.68 | 5.54 | ||
| Support 4 (S4) | 5.31 |
